Analyst Price Targets — ARVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 11:15 am | — | BTIG | $18.00 | $9.57 | TheFly | Arvinas price target raised to $18 from $16 at BTIG |
| May 13, 2026 8:57 am | — | Barclays | $20.00 | $9.57 | TheFly | Arvinas price target raised to $20 from $18 at Barclays |
| March 18, 2026 3:18 pm | Srikripa Devarakonda | Truist Financial | $10.00 | $10.96 | StreetInsider | Truist Securities Reiterates Hold Rating on Arvinas Inc. (ARVN) amid positive Parkinson's data |
| February 24, 2026 7:02 pm | — | Wedbush | $11.00 | $12.37 | TheFly | Arvinas price target raised to $11 from $9 at Wedbush |
| December 17, 2025 10:54 am | — | Barclays | $18.00 | $11.90 | TheFly | Arvinas price target raised to $18 from $16 at Barclays |
| October 30, 2025 10:05 am | Jeet Mukherjee | BTIG | $14.00 | $9.59 | StreetInsider | Arvinas Inc. (ARVN) PT Raised to $14 at BTIG |
| October 15, 2025 8:47 am | — | Goldman Sachs | $6.00 | $9.41 | TheFly | Arvinas downgraded to Sell from Neutral at Goldman Sachs |
| October 7, 2025 12:54 pm | — | Piper Sandler | $16.00 | $9.36 | TheFly | Arvinas price target raised to $16 from $14 at Piper Sandler |
| September 18, 2025 1:49 pm | — | BTIG | $10.00 | $7.92 | TheFly | Arvinas price target lowered to $10 from $16 at BTIG |
| September 18, 2025 10:43 am | Sudan Loganathan | Stephens | $14.00 | $7.75 | TheFly | Arvinas price target lowered to $14 from $16 at Stephens |
Latest News for ARVN
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.
NEW HAVEN, Conn. , May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings…
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARVN.
U.S. House Trading
No House trades found for ARVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.